1887
Volume 2014, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Innovations in drug-eluting stents (DES) have substantially reduced rates of in-segment restenosis and early stent thrombosis, improving clinical outcomes following percutaneous coronary interventions (PCI). However a fixed metallic implant in a vessel wall with restored patency and residual disease remains a precipitating factor for sustained local inflammation, in-stent neo-atherosclerosis and impaired vasomotor function increasing the risk for late complications attributed to late or very late stent thrombosis and late target lesion revascularization (TLR) (late catch-up).

The quest for optimal coronary stenting continues by further innovations in stent design and by using biocompatible materials other than cobalt chromium, platinum chromium or stainless steel for engineering coronary implants. Bioresorbable scaffolds made of biodegradable polymers or biocorrodible metals with properties of transient vessel scaffolding, local drug-elution and future restoration of vessel anatomy, physiology and local hemodynamics have been recently developed. These devices have been utilized in selected clinical applications so far providing preliminary evidence of safety showing comparable performance with current generation drug-eluting stents (DES).

Herein we provide a comprehensive overview of the current status of these technologies, we elaborate on the potential benefits of transient coronary scaffolds over permanent stents in the context of vascular reparation therapy, and we further focus on the evolving challenges these devices have to overcome to compete with current generation DES. The quest for optimizing percutaneous coronary interventions continues by iterative innovations in device materials beyond cobalt chromium, platinum chromium or stainless steel for engineering coronary implants. Bioresorbable scaffolds made of biodegradable polymers or biocorrodible metals with properties of transient vessel scaffolding; local drug-elution and future restoration of vessel anatomy, physiology and local hemodynamics were recently developed. These devices have been utilized in selected clinical applications providing preliminary evidence of safety showing comparable intermediate term clinical outcomes with current generation drug-eluting stents.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.55
2015-03-01
2019-12-13
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/4/gcsp.2014.55.html?itemId=/content/journals/10.5339/gcsp.2014.55&mimeType=html&fmt=ahah

References

  1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet Feb 4 1978; 1:8058:263.
    [Google Scholar]
  2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Jacques Goy J, van den Heuvel P, Delcan J, Morel M-A. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England Journal of Medicine. Aug 25 1994; 331:8:489495.
    [Google Scholar]
  3. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. Apr 1 2011; 4:2:195205.
    [Google Scholar]
  4. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. Jul 4 2006; 48:1:193202.
    [Google Scholar]
  5. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation Mar 20 2007; 115:11:14401445 discussion 1455.
    [Google Scholar]
  6. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguor C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet Apr 14 2012; 379:9824:13931402.
    [Google Scholar]
  7. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, Thrombosis, and Vascular Biology. Jul 2007; 27:7:15001510.
    [Google Scholar]
  8. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation Mar 6 2012; 125:9:11101121.
    [Google Scholar]
  9. Garg S, Serruys PW. Coronary stents: looking forward. Journal of the American College of Cardiology. Aug 31 2010; 56:10 Suppl:S4378.
    [Google Scholar]
  10. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC. Cardiovascular Interventions. Dec 2009; 2:12:11691177.
    [Google Scholar]
  11. Obata JE, Kitta Y, Takano H, Kodama Y, Nakamura T, Mende A, Kawabata K, Saitoh Y, Fujioka D, Kobayashi T, Yano T, Kugiyama K. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. Journal of the American College of Cardiology. Oct 2 2007; 50:14:13051309.
    [Google Scholar]
  12. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. Journal of the American College of Cardiology. Jun 5 2012; 59:23:20512057.
    [Google Scholar]
  13. Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. Eurolntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Jun 2010; 6:2:195205.
    [Google Scholar]
  14. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet Sep 27 2008; 372:9644:11631173.
    [Google Scholar]
  15. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC. Cardiovascular Interventions. Aug 2013; 6:8:777789.
    [Google Scholar]
  16. Gogas BD, McDaniel M, Samady H, King SB 3rd. Novel drug-eluting stents for coronary revascularization. Trends in Cardiovascular Medicine. Oct 2014; 24:7:305313.
    [Google Scholar]
  17. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate “rosy” prophecy. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Dec 15 2009; 5:Suppl F:F78.
    [Google Scholar]
  18. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation Oct 1 1996; 94:7:16901697.
    [Google Scholar]
  19. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. Journal of the American College of Cardiology. Apr 10 2012; 59:15:13371349.
    [Google Scholar]
  20. Thury A, Wentzel JJ, Vinke RV, Gijsen FJ, Schuurbiers JC, Krams R, de Feyter PJ, Serruys PW, Slager CJ. Images in cardiovascular medicine. Focal in-stent restenosis near step-up: roles of low and oscillating shear stress? Circulation Jun 11 2002; 105:23:e185187.
    [Google Scholar]
  21. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation Nov 1983; 68:5:951960.
    [Google Scholar]
  22. Van der Heiden K, Gijsen FJ, Narracott A, Hsiao S, Halliday I, Gunn J, Wentzel JJ, Evans PC. The effects of stenting on shear stress: relevance to endothelial injury and repair. Cardiovascular Research. Jul 15 2013; 99:2:269275.
    [Google Scholar]
  23. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? European Heart Journal. Jun 2012; 33:11:13251333.
    [Google Scholar]
  24. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nature Reviews. Molecular Cell Biology. Jan 2009; 10:1:5362.
    [Google Scholar]
  25. Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. Mar 2012; 33:5:606613.
    [Google Scholar]
  26. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis Mar 2012; 221:1:106112.
    [Google Scholar]
  27. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention Dec 15 2009; 5:Suppl F:F1522.
    [Google Scholar]
  28. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials Jan 1996; 17:2:103114.
    [Google Scholar]
  29. Vorpahl M, Finn AV, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Dec 15 2009; 5:Suppl F:F2835.
    [Google Scholar]
  30. Gogas BD, Farooq V, Onuma Y, Serruys PW. The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? Hellenic J Cardiol. Jul-Aug 2012; 53:4:301309.
    [Google Scholar]
  31. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation Nov 30 2010; 122:22:22882300.
    [Google Scholar]
  32. Gogas BD, Radu M, Onuma Y, Perkins L, Powers JC, Gomez-Lara J, Farooq V, Garcia-Garcia HM, Diletti R, Rapoza R, Virmani R, Serruys PW. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging. Mar 2012; 28:3:499511.
    [Google Scholar]
  33. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation Jul 25 2000; 102:4:399404.
    [Google Scholar]
  34. Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T, Takeuchi E, Inuzuka Y, Takeda S, Hata T, Takeuchi Y, Kawada Y, Harita T, Seki J, Akamatsu S, Hasegawa S, Bruining N, Brugaletta S, de Winter S, Muramatsu T, Onuma Y, Serruys PW, Ikeguchi S. Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation May 15 2012; 125:19:23432353.
    [Google Scholar]
  35. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart Jun 2003; 89:6:651656.
    [Google Scholar]
  36. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Böse D, Koolen J, Lüscher TF, Weissman N, Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet Jun 2 2007; 369:9576:18691875.
    [Google Scholar]
  37. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet Mar 9 2013; 381:9869:836844.
    [Google Scholar]
  38. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation May 11 2004; 109:18:21682171.
    [Google Scholar]
  39. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet Mar 15 2008; 371:9616:899907.
    [Google Scholar]
  40. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. Mar 14 2009; 373:9667:897910.
    [Google Scholar]
  41. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. Oct 2012; 5:5:620632.
    [Google Scholar]
  42. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention Dec 3 2013.
    [Google Scholar]
  43. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Garg S, Regar E, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Dorange C, Veldhof S, Morel MA, de Vries T, Ormiston JA, Serruys PW. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC. Cardiovascular Interventions. Nov 2010; 3:11:11901198.
    [Google Scholar]
  44. Gogas BD, Bourantas CV, Garcia-Garcia HM, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns RJ, De Bruyne B, Chevalier B, Thuesen L, Smits PC, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston JA, Serruys PW. The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials. Eurolntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Oct 22 2013; 9:6:709720.
    [Google Scholar]
  45. Gogas BD, Garcia-Garcia HM, Onuma Y, Muramatsu T, Farooq V, Bourantas CV, Serruys PW. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds. JACC. Cardiovascular Interventions. Mar 2013; 6:3:211221.
    [Google Scholar]
  46. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A Next-Generation Bioresorbable Coronary Scaffold System-From Bench to First Clinical Evaluation: Six- and 12-Month Clinical and Multimodality Imaging Results. JACC Cardiovasc Interv. 2014 Jan; 7:1:8999.
    [Google Scholar]
  47. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv. Aug 1 2008; 72:2:186194.
    [Google Scholar]
  48. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention Dec 15 2009; 5:Suppl F:F5864.
    [Google Scholar]
  49. Zeltinger J. Bio-Mechanical properties & ABC of Tyrosine polycarbonate. PCR FOCUS GROUP 2012. Oral presentation.
  50. Lafont A, Durand E. A.R.T.: concept of a bioresorbable stent without drug elution. EuroIntervention Dec 15 2009; 5:Suppl F:F8387.
    [Google Scholar]
  51. Waksman R, Prati F, Bruining N, Haude M, Böse D, Kitabata H, Erne P, Verheye S, Degen H, Vermeersch P, Di Vito L, Koolen J, Erbel R. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment. Circ Cardiovasc Interv. Dec 1 2013; 6:6:644653.
    [Google Scholar]
  52. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. Journal of the American College of Cardiology. Oct 4 2011; 58:15:15781588.
    [Google Scholar]
  53. Gogas BD, Yang B, Passerini T, Veneziani A, Piccinelli M, Esporito G, Rasoul-Arzrumly E, Awad M, Mekonnen G, Hung OY, Holloway B, McDaniel M, Giddens DP, King SB III, Samady H. Computational Fluid Dynamics Applied to Virtually Deployed Drug-Eluting Coronary Bioresorbable Scaffolds. Clinical Translations Derived from a Proof-of-Concept. GCSP Dec 31 2014; 2014:4:56.
    [Google Scholar]
  54. Nieman K, Serruys PW, Onuma Y, van Geuns R-J, Garcia-Garcia HM, de Bruyne B, Thuesen L, Smits PC, Koolen JJ, McClean D, Chevalier B, Meredith I, Ormiston J. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol. Nov 5 2013; 62:19:18131814.
    [Google Scholar]
  55. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schühlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation Jun 12 2001; 103:23:28162821.
    [Google Scholar]
  56. Pache J, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Müller M, Dirschinger J, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. Apr 16 2003; 41:8:12831288.
    [Google Scholar]
  57. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. Mar 2013; 6:3:247257.
    [Google Scholar]
  58. Farooq V, Serruys PW, Heo JH, Gogas BD, Onuma Y, Perkins LE, Diletti R, Radu MD, Räber L, Bourantas CV, Zhang Y, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom HM, Garcìa-Garcìa HM, Virmani R. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC. Cardiovascular Interventions. May 2013; 6:5:523532.
    [Google Scholar]
  59. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. Oct 1 2011; 4:5:535538.
    [Google Scholar]
  60. Farooq V, Gomez-Lara J, Brugaletta S, Gogas BD, Garcìa-Garcìa HM, Onuma Y, van Geuns RJ, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. May 1 2012; 79:6:880888.
    [Google Scholar]
  61. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation Oct 17 2006; 114:16:17361743, discussion 1744.
    [Google Scholar]
  62. Schafer PE, Sacrinty MT, Cohen DJ, Kutcher MA, Gandhi SK, Santos RM, Little WC, Applegate RJ. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes. Jul 2011; 4:4:408415.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.55
Loading
/content/journals/10.5339/gcsp.2014.55
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error